labetalol + nifedipine

A combination of labetalol (a mixed alpha- and beta-adrenergic blocker) and nifedipine (a calcium channel blocker) used primarily for blood pressure control in specific clinical scenarios. This combination leverages the complementary mechanisms of action of both medications to achieve effective blood pressure management, particularly in pregnancy-induced hypertension (PIH) and during electroconvulsive therapy (ECT) in elderly patients. Labetalol is a mixed alpha- and beta-blocker that effectively controls heart rate and blood pressure. It works by blocking both alpha and beta adrenergic receptors, which helps reduce peripheral resistance and cardiac output, leading to decreased blood pressure. Its advantage in pregnancy-related hypertension lies in its ability to control blood pressure without significantly affecting placental blood flow, which is crucial for fetal well-being. Nifedipine is a calcium channel blocker that primarily causes vasodilation, reducing peripheral vascular resistance and subsequently lowering blood pressure. It has additional benefits including increasing prostacyclin levels, preventing platelet aggregation, and promoting fetal lung maturation in pregnant patients.

Other names

CHAP interventionAntihypertensive therapy (CHAP)